Related Experiment Video

Updated: Sep 3, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Suppression of Chromosome Instability Limits Acquired Drug Resistance

Elizabeth A Crowley1, Nicole M Hermance1, Conor P Herlihy1

  • 1Department of Biology and Biotechnology, Worcester Polytechnic Institute, Worcester, Massachusetts.

Molecular Cancer Therapeutics
|July 29, 2022
PubMed

Insights

Numerical chromosome instability (nCIN) drives tumor evolution and drug resistance in lung cancer. Suppressing nCIN limits tumor heterogeneity and alters resistance mechanisms without affecting proliferation, suggesting nCIN inhibition as a therapeutic strategy.

Area of Science:

  • Oncology
  • Genetics
  • Cell Biology

Background:

  • Numerical chromosome instability (nCIN), characterized by whole chromosome gains/losses, is common in solid tumors.
  • nCIN promotes tumor heterogeneity, aggressiveness, drug resistance, and relapse.
  • Therapeutic modulation of nCIN for cancer treatment remains largely unexplored.

Purpose of the Study:

  • To investigate the role of nCIN in the development of drug resistance in non-small cell lung cancer (NSCLC).
  • To explore the potential of modulating nCIN as a therapeutic strategy in NSCLC.

Main Methods:

  • Assessed nCIN in NSCLC cells by manipulating microtubule dynamics and chromosome cohesion.
  • Evaluated the impact of nCIN suppression on tumor cell proliferation and initiation in vitro and in mouse xenograft models.
  • Analyzed the effects of nCIN suppression on the timing and molecular mechanisms of acquired drug resistance.

Main Results:

  • nCIN generation in NSCLC cells is sensitive to microtubule dynamics.
  • Enhancing chromosome cohesion significantly suppressed nCIN and reduced intratumor heterogeneity.
  • nCIN suppression did not affect NSCLC cell proliferation or tumor initiation.
  • Suppression of nCIN altered the mechanisms and timing of acquired drug resistance.

Conclusions:

  • nCIN plays a critical role in driving acquired drug resistance in NSCLC.
  • Suppression of nCIN can limit tumor evolution and potentially sustain drug response.
  • Targeting nCIN represents a promising therapeutic avenue for NSCLC treatment and overcoming drug resistance.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.3K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K